JPRN-UMIN000014386招募中2 期
A multicentre,single arm,confirmatory trial to evaluate the effectiveness of induction CDDP plus TS-1 with concurrent radiotherapy(66Gy) followed by surgical resection in patients with superior sulcus tumor. - Superior sulcus tumor Induction Therapy Clinical Trial(SST)
Advanced Clinical Trial chest surgery Group (ACTG)0 个研究点目标入组 80 人开始时间: 2014年6月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Distant metastasis (2) malignant pleural effusion, pericardial effusionintrathoracic seeding. (3) Uncontrollable systemic disease (hyper tension, diabetes mellitus etc.) (4) Case with the administration of the flucytosine. (5) Severe drug allergy (6) Infection requiring intravenous administration of anti-viral agents antibiotics, or antifungals (7) Hepatitis Bs antigen positive (8) History of severe heart disease , Current or previous (within the last 1 year) history of myocardial infarction (9) Traumatic fracture of unrecovery ,a high degree of wound (10) Severe diarrhea (11) Investigational new drug or the unapproved drug is administered (12) Interstitial pneumonia or pulmonary fibrosis detectable on chest CT (13) History of active double cancer (14) History of pregnancy or lactation or Women suspected of being pregnant.Men who wish to make a child. or no intention to contraception (15) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator
研究者
相似试验
进行中（未招募）
2 期
CRES3TPrimary lung cancerSuperior sulcus tumorJPRN-jRCTs031180401Suzuki Kenji60
进行中（未招募）
1 期
A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary ImmunodeficiencyPrimary Immunodeficiency (PI) diseasesMedDRA version: 20.1Level: LLTClassification code 10045792Term: Unspecified disorder of immune mechanismSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0Level: PTClassification code 10061598Term: ImmunodeficiencySystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0Level: PTClassification code 10064859Term: Primary immunodeficiency syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003290-15-PLGrifols Therapeutics Inc.61
进行中（未招募）
1 期
A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary ImmunodeficiencyEUCTR2015-003290-15-HUGrifols Therapeutics Inc.60
进行中（未招募）
1 期
A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary ImmunodeficiencyPrimary Immunodeficiency (PI) diseasesMedDRA version: 20.0 Level: PT Classification code 10061598 Term: Immunodeficiency System Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1 Level: LLT Classification code 10045792 Term: Unspecified disorder of immune mechanism System Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0 Level: PT Classification code 10064859 Term: Primary immunodeficiency syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003290-15-FRGrifols Therapeutics Inc.60
进行中（未招募）
1 期
A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary ImmunodeficiencyEUCTR2015-003290-15-GBGrifols Therapeutics Inc.61